MétaCan
Menu
Back to cohort

Comorbidity and overall survival (OS) in cetuximab-treated patients with advanced colorectal cancer (ACRC)—Results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care (BSC)

2009· article· en· W2248026357 on OpenAlexaff
Erin Powell, Timothy R. Asmis, Derek J. Jonker, Dehao Tu, Christos S. Karapetis, Mark Jeffery, Christopher J. O’Callaghan

Bibliographic record

VenueJournal of Clinical Oncology · 2009
Typearticle
Languageen
FieldMedicine
TopicColorectal Cancer Treatments and Studies
Canadian institutionsOttawa Regional Cancer Foundation
Fundersnot available
KeywordsMedicineComorbidityInternal medicineCetuximabUnivariate analysisRandomizationKRASMultivariate analysisGastroenterologyRandomized controlled trialCancerColorectal cancer

Abstract

fetched live from OpenAlex

4074 Background: The interplay between comorbidity, age and performance status (PS) as predictors of outcome in ACRC is not well described. We examined these factors as predictors of treatment toxicity and outcome in cetuximab-treated patients with ACRC. Methods: Comorbidity was independently evaluated by 2 physicians using the Charlson Comorbidity Index (CCI), a previously validated measure of comorbidity based on the presence or absence of index medical conditions weighted according to their affect on mortality. CCI score was correlated with demographic data (age, gender), PS, site of primary, time from diagnosis to randomization, body mass index, hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), creatinine clearance, K-ras status and OS. Results: 572 patients were included. 41% were ≥65 years and 25% had comorbidities at randomization. CCI score was 1 in 21% and ≥ 2 in 4%. In multivariate analysis (MVA) of all covariates, only older age (≥65 years) was associated with greater comorbidity (p=0.005). OS was different among 3 comorbidity groups (CCI score 0, 1, ≥ 2) in univariate analysis (median OS 4.9 vs 5.9 vs 4.8 months;, logrank p=0.04) but not in MVA. Conversely, lower PS remained associated with better OS in MVA (HR 1.96 for PS=2 vs. PS=0, p<0.0001). Age was not associated with OS (p=0.11). Other factors significantly associated with OS in MVA included time from diagnosis to randomization, LDH, ALP, hemoglobin, Kras status and cetuximab treatment. In the BSC arm, comorbidity was not associated with OS in MVA (HR 0.83 CCI 1 vs. CCI0, p=0.26 and HR 0.90 for CCI2 vs. CCI0, p=0.78) suggesting comorbidity is not prognostic in this setting. Patients with higher CCI score had a nonsignificant trend toward greater treatment effects. Patients ≥65 years had less gr≥3 vomiting (1.8 vs 7.9%, p=0.034) but more dyspnea (24.5 vs 11.2%, p=0.005). Patients with higher CCI scores had less vomiting (p=0.008) but more non-neutropenic infection (p=0.012). Conclusions: In this clinical trial, comorbidity and age were not independent predictors of survival, highlighting the difference between comorbidity and PS. [Table: see text]

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.085
GPT teacher head0.459
Teacher spread0.374 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2009
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicColorectal Cancer Treatments and StudiesFrench-language works237,207